UTHR:NASDAQUnited Therapeutics Corporation Analysis

United Therapeutics is trading at $553, just above its recent support of $535 and below the 20‑day SMA of $556, while the MACD has turned bearish and volume is slipping, signaling short‑term pressure. The stock’s RSI sits near 48, indicating a neutral momentum environment, and the market sentiment is at an "Extreme Greed" level on the Fear & Greed Index. Recent earnings were disappointing, with revenue down 1.6% YoY and GAAP EPS missing estimates by over 15%, which contributed to a -13.6% earnings surprise. Despite the near‑term headwinds, the company boasts a 86% gross margin, a 41% operating margin, and a cash pile exceeding $2 billion with zero debt, underscoring a robust balance sheet.
Looking ahead, the pipeline shows promise—most notably the phase‑3 ADVANCE OUTCOMES trial of Ralinepag met its primary endpoint with a 55% risk reduction, offering a potential catalyst. Analysts remain bullish, averaging a price target of $665, and the forward PE of 17.4 suggests earnings growth is priced in. However, the DCF fair value of roughly $227 is far below the current price, implying the stock may be overvalued relative to intrinsic estimates. Overall, the fundamentals are strong, but the technicals and recent earnings miss temper short‑term optimism.